By


Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate
Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids    

See more here

By


Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

See more here

By


ENB Therapeutics Closes Series A Round of Funding
Remiges led the Series A round of Financing  

See more here

By


Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Trial Enrolling Well, with Approximately 25% of Targeted Subjects Recruited Top-line Data Expected in First Half of 2019  

See more here

By


Group K Diagnostics is the Technology Category Winner in the 2018 Stellar Startup Awards

See more here

By


Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
– Dr. Heron Adds Deep Expertise in Orphan Drug Development and Commercialization –  

See more here

By


Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

See more here

By


Cohero Health Announces Additions to Executive Leadership Team
Company appoints executives with proven industry experience in connected care, medical device, and pharma to drive growth of the BreathSmart® digital platform for asthma and COPD 

See more here